On June 15, 2026, the National Institutes of Health (NIH) announced that moving forward, NICEATM will continue its important work as a division of the newly created NIH Office of Research Innovation, Validation, and Application (ORIVA). Soon, NICEATM content that you see on this webpage will be transitioned to the NIH ORIVA webpage. In the meantime, you can learn more about the new office and how it is structured.

https://ntp.niehs.nih.gov/go/developers-forums

Method Developers Forums

New Approaches for Cardiovascular Toxicity Testing

The main event for this Method Developers Forum is not yet scheduled. 

ICCVAM is inviting NAMs end-users from the industry sector (e.g., pharmaceutical and chemical companies) to record a brief presentation summarizing their information requirements and/or decision frameworks relevant to cardiovascular toxicity. Stakeholders are also invited to participate in the MDF as panelists, providing feedback to NAMs developers on each method’s readiness. Interested individuals should email [email protected].

As a follow-up to publication of the report on Validation, Qualification, and Regulatory Acceptance of New Approach Methodologies, ICCVAM and NICEATM will organize a series of Method Developers Forums (MDFs), each focused on a specific endpoint/toxicity. These forums will provide an opportunity for NAMs developers to present their methods and regulatory issues with relevant stakeholders.

The next ICCVAM MDF will focus on NAMs for cardiovascular toxicity testing. The preparation of videos that summarize regulatory and industry stakeholders’ information requirements and/or decision frameworks relevant to cardiovascular toxicity is in progress. Instructions for developers on submitting method proposals will be posted on this webpage as it becomes available.

Please contact NICEATM for information on the opportunity to prepare a video for this MDF.